# Diabetes Mellitus > This is general, educational information — not individualized medical advice, and not a substitute for your care team. For decisions about your own health, or in an emergency, contact your doctor or local emergency services. A group of conditions marked by high blood glucose from impaired insulin production, insulin resistance, or both — spanning type 1, type 2, gestational, and the less-common monogenic and LADA forms. ## In this guide - Overview, Types & Classification - Causes & Pathophysiology - Diagnosis & Monitoring Tests - Acute Emergencies (Red Flags) - Medications & Insulin - Devices & Technology - Key Drug Interactions - Therapy & Lifestyle - Patient Care & Self-Management - Chronic Complications - Comorbidities & Co-occurring Conditions - Experimental & Emerging Therapies - Complementary & Integrative Approaches --- ## Overview, Types & Classification What diabetes is, how the main types differ (type 1, type 2, gestational, prediabetes, MODY, LADA), and the scale of the condition. ### What diabetes is **Diabetes is a group of conditions in which blood glucose (blood sugar) runs too high because the body makes too little insulin, cannot use it well, or both.** Diabetes mellitus is a chronic condition defined by raised blood glucose. After we eat, carbohydrate is broken down into glucose, which enters the bloodstream; the hormone insulin, made by beta cells in the pancreas, lets glucose move into cells for energy. In diabetes this system fails — either the pancreas makes little or no insulin, the body's cells respond poorly to insulin (insulin resistance), or both — so glucose builds up in the blood. Persistently high glucose, over years, damages blood vessels and nerves and drives the long-term complications of diabetes. The main types differ in cause, but all share elevated glucose as the core problem. **Sources:** - [What Is Diabetes?](https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes) — NIH / NIDDK - [Diabetes Basics](https://www.cdc.gov/diabetes/about/index.html) — CDC ### Type 1 diabetes **Type 1 is an autoimmune disease in which the immune system destroys the insulin-making beta cells, so the body makes essentially no insulin and lifelong insulin treatment is required.** Type 1 diabetes (T1D) accounts for roughly 5–10% of diabetes. It is an autoimmune condition: the immune system mistakenly attacks and destroys the pancreatic beta cells that make insulin. As insulin production fails, glucose can no longer enter cells, and without replacement insulin the body breaks down fat for fuel, producing acid ketones that can cause a life-threatening emergency (diabetic ketoacidosis). T1D often appears in childhood or adolescence but can begin at any age. It is not caused by diet or lifestyle and cannot currently be prevented or cured; everyone with T1D needs insulin, delivered by injection or pump, to live. **Sources:** - [Type 1 diabetes — Symptoms and causes](https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/symptoms-causes/syc-20353011) — Mayo Clinic - [Understanding Type 1 Diabetes](https://diabetes.org/about-diabetes/type-1) — American Diabetes Association ### Type 2 diabetes **Type 2 is the most common form: the body becomes resistant to insulin and the pancreas can't keep up, so glucose rises. It is strongly linked to genetics, weight, and lifestyle.** Type 2 diabetes (T2D) makes up about 90–95% of cases. It develops when the body's cells respond poorly to insulin (insulin resistance) and, over time, the pancreas can no longer produce enough insulin to overcome that resistance. Risk rises with age, family history, excess weight (especially around the abdomen), physical inactivity, and certain ethnic backgrounds. T2D often develops gradually and can be present for years with few symptoms, so many people are diagnosed late or after a complication appears. Unlike type 1, type 2 can often be improved — and sometimes pushed into remission — through weight loss, dietary change, and activity, alongside medication when needed. **Sources:** - [Type 2 diabetes — Symptoms and causes](https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/symptoms-causes/syc-20351193) — Mayo Clinic - [Understanding Type 2 Diabetes](https://diabetes.org/about-diabetes/type-2) — American Diabetes Association ### Prediabetes **Prediabetes means blood glucose is higher than normal but not yet in the diabetes range — a strong warning sign, and often reversible.** In prediabetes, blood glucose is elevated but below the threshold for type 2 diabetes (for example, an A1c of 5.7–6.4%, a fasting glucose of 100–125 mg/dL, or an OGTT 2-hour value of 140–199 mg/dL). It usually has no symptoms, yet it substantially raises the risk of progressing to type 2 diabetes and of cardiovascular disease. The important message is that prediabetes is often reversible: structured lifestyle programs emphasizing modest weight loss and increased physical activity (and, in some people, metformin) can significantly cut the chance of developing diabetes. Identifying prediabetes is a key opportunity for prevention. **Sources:** - [Diabetes Tests & Diagnosis (prediabetes ranges)](https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis) — NIH / NIDDK - [Diabetes Basics — prediabetes](https://www.cdc.gov/diabetes/about/index.html) — CDC ### Gestational diabetes **Gestational diabetes is high blood glucose first recognized in pregnancy; it usually resolves after birth but raises later type 2 risk for the parent.** Gestational diabetes mellitus (GDM) develops during pregnancy, typically in the second or third trimester, when pregnancy hormones increase insulin resistance and the pancreas can't keep up. It usually causes no obvious symptoms and is found through routine screening (often an oral glucose tolerance test). Well-managed GDM — through monitoring, nutrition, activity, and insulin or other medication when needed — protects both parent and baby; poorly controlled GDM raises risks such as a large baby, delivery complications, and neonatal low blood sugar. Glucose usually returns to normal after delivery, but a history of GDM markedly increases the lifetime risk of type 2 diabetes, so follow-up testing is recommended. **Sources:** - [Gestational Diabetes](https://diabetes.org/about-diabetes/gestational-diabetes) — American Diabetes Association - [Symptoms & Causes of Diabetes (gestational)](https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes) — NIH / NIDDK ### Monogenic diabetes (MODY and neonatal) **A small share of diabetes comes from a single inherited gene change — including MODY in young adults and neonatal diabetes in infants — and some forms respond to specific treatments.** Monogenic diabetes results from a mutation in a single gene and accounts for roughly 1–4% of diabetes in the U.S. The two main groups are maturity-onset diabetes of the young (MODY), which usually appears in adolescence or early adulthood, and neonatal diabetes mellitus, which appears in infants under about 6–12 months. More than 40 subtypes are known; mutations in the HNF1A and GCK genes are among the most common. Monogenic diabetes is frequently misdiagnosed as type 1 or type 2. Getting the genetic diagnosis right matters because treatment can differ sharply — for example, certain MODY and neonatal forms are well controlled with oral sulfonylureas rather than insulin, and GCK-MODY often needs no treatment at all. **Sources:** - [Monogenic Diabetes (Neonatal Diabetes Mellitus & MODY)](https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/monogenic-neonatal-mellitus-mody) — NIH / NIDDK ### LADA (latent autoimmune diabetes in adults) **LADA is a slowly developing form of type 1 autoimmune diabetes that appears in adulthood and is often mistaken at first for type 2.** Latent autoimmune diabetes in adults (LADA) is sometimes called 'type 1.5' diabetes. Like type 1, it is autoimmune — the immune system gradually destroys beta cells, and islet autoantibodies (such as GAD antibodies) are usually present — but it develops slowly in adults, who may not need insulin for months or years after diagnosis. Because it looks like type 2 at first, LADA is often initially misclassified. Recognizing it matters because insulin is typically needed sooner than in type 2, and the management approach differs. Clinicians may suspect LADA in an adult with 'type 2' who is not overweight, has other autoimmune conditions, or responds poorly to oral medications; antibody and C-peptide testing help clarify the diagnosis. **Sources:** - [Latent autoimmune diabetes in adults (LADA): What is it?](https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/expert-answers/lada-diabetes/faq-20057880) — Mayo Clinic ### How common diabetes is **Diabetes is one of the most common chronic diseases worldwide, affecting hundreds of millions of people, with type 2 accounting for the large majority.** Diabetes is a major and growing global health problem. Hundreds of millions of adults live with it worldwide, and a large fraction — especially with type 2 — are undiagnosed. In the United States, more than one in ten people have diabetes and roughly a third of adults have prediabetes. Type 2 makes up about 90–95% of cases; type 1 about 5–10%; the remainder are gestational, monogenic, and other forms. Prevalence is rising with aging populations, urbanization, and increasing obesity. Diabetes is a leading cause of blindness, kidney failure, lower-limb amputation, heart attack, and stroke, which is why prevention, early diagnosis, and good ongoing care matter so much. **Sources:** - [Diabetes Basics — statistics and overview](https://www.cdc.gov/diabetes/about/index.html) — CDC - [What Is Diabetes? — scope](https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes) — NIH / NIDDK --- ## Causes & Pathophysiology Why blood glucose rises: normal insulin physiology, autoimmune beta-cell destruction in type 1, insulin resistance in type 2, and the genetic and environmental risk factors behind each. ### How insulin and glucose normally work **Insulin is the key that lets glucose into cells; it also tells the liver when to store versus release glucose, keeping blood sugar in a narrow range.** Blood glucose is normally held within a tight range by insulin and its counter-hormone glucagon. When you eat, glucose rises and the pancreatic beta cells release insulin, which acts like a key: it lets glucose move from the blood into muscle and fat cells for energy and signals the liver to store glucose as glycogen and stop making new glucose. Between meals, insulin falls and glucagon rises, prompting the liver to release stored glucose so the brain and body keep a steady supply. Diabetes is, at root, a breakdown of this regulation — too little insulin, poor response to insulin, or both — and understanding the normal loop makes the different diabetes types and their treatments easier to follow. **Sources:** - [What Is Diabetes? — insulin and glucose](https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes) — NIH / NIDDK ### Type 1: autoimmune beta-cell destruction **In type 1, the immune system attacks the insulin-producing beta cells, leading to near-total insulin deficiency over months to years.** Type 1 diabetes is driven by an autoimmune process in which T cells of the immune system target and progressively destroy the insulin-producing beta cells in the pancreatic islets. This is thought to begin when a genetic susceptibility (strongly linked to certain HLA immune genes) combines with one or more environmental triggers that are not fully understood. The destruction unfolds over months to years; islet autoantibodies can often be detected in the blood well before symptoms appear, defining a presymptomatic phase. By the time symptoms emerge, most beta-cell capacity is already lost, so the body can no longer make enough insulin. The result is absolute insulin deficiency, which is why insulin replacement is essential and why type 1 is not caused by diet or weight. **Sources:** - [Type 1 diabetes — causes](https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/symptoms-causes/syc-20353011) — Mayo Clinic - [Symptoms & Causes of Diabetes](https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes) — NIH / NIDDK ### Type 2: insulin resistance and beta-cell decline **Type 2 begins with cells responding poorly to insulin; the pancreas compensates by making more, until it can no longer keep up and glucose rises.** Type 2 diabetes develops from two problems working together. First is insulin resistance: muscle, fat, and liver cells respond less effectively to insulin, so more is needed to move glucose out of the blood. For a while the beta cells compensate by pumping out extra insulin, and glucose stays normal. Over time, however, the beta cells become unable to sustain that overproduction — a relative insulin deficiency — and blood glucose climbs into the diabetes range. Excess body fat, particularly visceral (abdominal) fat and fat in the liver, is closely tied to insulin resistance, which helps explain why weight loss can dramatically improve type 2 and sometimes induce remission. Because the beta cells still make some insulin, type 2 usually does not cause ketoacidosis in everyday circumstances, though it can during severe illness. **Sources:** - [Type 2 diabetes — causes](https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/symptoms-causes/syc-20351193) — Mayo Clinic - [Symptoms & Causes of Diabetes](https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes) — NIH / NIDDK ### Type 1 risk: genes and triggers **Type 1 risk is partly genetic (especially HLA genes) but most people who develop it have no family history; environmental triggers are still being studied.** Type 1 diabetes arises from a combination of genetic susceptibility and environmental factors. The strongest genetic contribution comes from HLA genes that shape immune responses, with other genes adding smaller effects. Having a close relative with type 1 modestly increases risk, but most people who develop it have no affected family member, and inheriting susceptibility genes is not enough on its own. Researchers are investigating environmental triggers — certain viral infections have been studied, for example — but no single cause has been confirmed, and importantly, type 1 is not caused by eating sugar, diet, or anything a person or parent did. Screening for islet autoantibodies in relatives can identify people in the early, presymptomatic stages of the disease. > **Note:** Risk factors describe populations, not individuals — they do not explain why one specific person developed type 1. **Sources:** - [Type 1 diabetes — risk factors](https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/symptoms-causes/syc-20353011) — Mayo Clinic - [Understanding Type 1 Diabetes — risk](https://diabetes.org/about-diabetes/type-1) — American Diabetes Association ### Type 2 risk factors **Type 2 risk reflects a mix of genetics, age, family history, excess weight, inactivity, and ethnicity — some modifiable, some not.** Type 2 diabetes results from interacting risk factors. Non-modifiable factors include older age, a family history of type 2, and ethnicity (people of South Asian, African, African-Caribbean, Hispanic/Latino, Native American, and several other backgrounds are at higher risk). Modifiable factors include excess body weight — especially abdominal fat — physical inactivity, and elements of diet. Other associations include a history of gestational diabetes, polycystic ovary syndrome, high blood pressure, and abnormal cholesterol. The strong link to modifiable factors is the basis of prevention: in high-risk people, structured lifestyle change with modest weight loss and increased activity substantially lowers the chance of progressing from prediabetes to type 2 diabetes. Risk factors describe probability across populations, not certainty for any individual. **Sources:** - [Type 2 diabetes — risk factors](https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/symptoms-causes/syc-20351193) — Mayo Clinic - [Type 2 diabetes — causes and risk (NHS)](https://www.nhs.uk/conditions/type-2-diabetes/) — NHS (UK) ### Why gestational diabetes happens **Hormones from the placenta increase insulin resistance in pregnancy; when the pancreas can't keep up, gestational diabetes develops.** During pregnancy, the placenta produces hormones that help the baby grow but also make the pregnant person's tissues more resistant to insulin — a normal adaptation that tends to peak in the second and third trimesters. To maintain normal glucose, the pancreas must produce substantially more insulin. Gestational diabetes develops when beta-cell output can't rise enough to overcome this added resistance, so glucose climbs. Risk is higher with excess weight before pregnancy, older age, a family history of type 2 diabetes, prior gestational diabetes, and certain ethnic backgrounds. Because the underlying tendency toward insulin resistance often persists, people who have had gestational diabetes carry a markedly higher long-term risk of type 2 diabetes and benefit from ongoing screening. **Sources:** - [Gestational Diabetes — causes](https://diabetes.org/about-diabetes/gestational-diabetes) — American Diabetes Association - [Symptoms & Causes of Diabetes (gestational)](https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes) — NIH / NIDDK --- ## Diagnosis & Monitoring Tests How diabetes and prediabetes are diagnosed — A1c, fasting glucose, OGTT, and random glucose with their cutoffs — and the antibody and C-peptide tests used to tell type 1 from type 2. ### The A1c test **A1c reflects average blood glucose over about 2–3 months; 6.5% or higher (on two tests) indicates diabetes, and 5.7–6.4% indicates prediabetes.** Hemoglobin A1c (HbA1c) measures the percentage of hemoglobin in red blood cells that has glucose attached, giving an average of blood glucose over the prior roughly 2–3 months. It needs no fasting and is widely used both to diagnose and to monitor diabetes. Diagnostic thresholds: A1c below 5.7% is normal, 5.7–6.4% is prediabetes, and 6.5% or higher indicates diabetes (a diagnosis is generally confirmed with a repeat or a second test type). A1c can be misleading in some situations — pregnancy, recent blood loss or transfusion, certain anemias, and some hemoglobin variants — where glucose-based tests are preferred. Once diagnosed, A1c is also the main long-term control metric, with individualized targets (commonly around 7% for many adults, but higher or lower depending on the person). **Sources:** - [Diabetes Tests & Diagnosis](https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis) — NIH / NIDDK - [2. Diagnosis and Classification of Diabetes (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566/2-Diagnosis-and-Classification-of-Diabetes) — American Diabetes Association — Diabetes Care, 2025 ### Fasting glucose, OGTT, and random glucose **Diabetes can also be diagnosed by fasting glucose ≥126 mg/dL, a 2-hour OGTT value ≥200 mg/dL, or a random glucose ≥200 mg/dL with classic symptoms.** Besides A1c, three glucose-based tests diagnose diabetes. The fasting plasma glucose (FPG) is measured after at least 8 hours without eating: below 100 mg/dL is normal, 100–125 mg/dL is prediabetes, and 126 mg/dL or higher indicates diabetes. The oral glucose tolerance test (OGTT) measures glucose 2 hours after drinking a standard 75 g glucose solution: below 140 is normal, 140–199 is prediabetes, and 200 mg/dL or higher indicates diabetes; the OGTT is also the standard for gestational diabetes screening. A random (any-time) plasma glucose of 200 mg/dL or higher, together with classic symptoms such as excessive thirst, frequent urination, and unexplained weight loss, also makes the diagnosis. Apart from an unequivocally high random glucose with symptoms, results are normally confirmed with a repeat test. **Sources:** - [Diabetes Tests & Diagnosis (FPG, OGTT, random)](https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis) — NIH / NIDDK - [2. Diagnosis and Classification of Diabetes (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566/2-Diagnosis-and-Classification-of-Diabetes) — American Diabetes Association — Diabetes Care, 2025 ### Islet autoantibodies **Autoantibodies against beta-cell proteins (such as GAD, IA-2, ZnT8, and insulin) mark the autoimmune diabetes of type 1 and LADA.** Islet autoantibodies are immune proteins directed against components of the insulin-producing beta cells, and their presence signals an autoimmune cause. The main ones tested are GAD65 (glutamic acid decarboxylase), IA-2, zinc transporter 8 (ZnT8), and insulin autoantibodies. They are typically present in type 1 diabetes and in LADA, and absent in type 2 and most monogenic diabetes, so antibody testing helps classify the diabetes type — especially in adults where type 1/LADA can be mistaken for type 2, or in children with atypical features. Autoantibodies can also be detected before symptoms begin: having two or more is now used to define early-stage type 1 diabetes in at-risk individuals, which underpins screening programs and the use of prevention therapy. **Sources:** - [2. Diagnosis and Classification of Diabetes (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566/2-Diagnosis-and-Classification-of-Diabetes) — American Diabetes Association — Diabetes Care, 2025 ### C-peptide — measuring your own insulin **C-peptide is released alongside insulin, so it estimates how much insulin a person still makes — low in type 1, often normal or high in type 2.** When beta cells make insulin, they release it together with a fragment called C-peptide in equal amounts. Because injected insulin contains no C-peptide, measuring C-peptide gives a picture of how much insulin the body itself is still producing. Levels tend to be low or undetectable in established type 1 diabetes (little endogenous insulin), and normal or high in type 2 (where the problem is insulin resistance, at least early on). C-peptide can therefore help classify uncertain cases — for example, distinguishing long-standing type 1 from type 2, evaluating possible LADA, or clarifying monogenic diabetes — and is interpreted alongside the clinical picture and autoantibody results rather than on its own. **Sources:** - [2. Diagnosis and Classification of Diabetes (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566/2-Diagnosis-and-Classification-of-Diabetes) — American Diabetes Association — Diabetes Care, 2025 ### Telling the types apart **Classification combines the clinical picture with antibody and C-peptide testing; getting it right changes treatment, especially for type 1, LADA, and monogenic diabetes.** Correctly classifying diabetes guides treatment, but it is not always obvious from glucose numbers alone. Clinicians weigh the clinical picture (age at onset, body weight, speed of onset, family history, presence of ketoacidosis, response to oral medication) together with islet autoantibodies and, when needed, C-peptide and genetic testing. Misclassification is common — adults with type 1 or LADA are sometimes labeled type 2 and undertreated, while young people with monogenic diabetes may be mislabeled type 1 and given unnecessary insulin. The stakes are practical: type 1 and LADA need insulin (sooner in LADA than its 'type 2' appearance suggests), certain monogenic forms respond to sulfonylureas or need no treatment, and type 2 has the widest menu of options. When the type is unclear, specialist evaluation and antibody/C-peptide testing are warranted. > **Note:** When the diabetes type is uncertain or treatment isn't working as expected, ask the care team about antibody, C-peptide, or genetic testing — classification is a clinical decision. **Sources:** - [2. Diagnosis and Classification of Diabetes (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566/2-Diagnosis-and-Classification-of-Diabetes) — American Diabetes Association — Diabetes Care, 2025 - [Diabetes Tests & Diagnosis](https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis) — NIH / NIDDK --- ## Acute Emergencies (Red Flags) Recognizing diabetes emergencies: low blood sugar (hypoglycemia) including severe lows, and the high-glucose crises DKA and HHS — what they look like and when to get urgent help. ### Hypoglycemia (low blood sugar) — recognizing it **Low blood sugar (commonly below 70 mg/dL) can cause shakiness, sweating, hunger, confusion, and irritability, and needs prompt treatment with fast-acting carbohydrate.** Hypoglycemia means blood glucose has dropped too low — often defined as below 70 mg/dL (3.9 mmol/L), with more serious effects below 54 mg/dL. It is most common in people taking insulin or insulin-stimulating pills (sulfonylureas), and can be triggered by too much medication, skipped or delayed meals, extra activity, or alcohol. Early warning signs include shakiness, sweating, a fast heartbeat, hunger, anxiety, tingling lips, dizziness, and difficulty concentrating; as it worsens, confusion, slurred speech, irritability, and clumsiness appear. The usual self-treatment is the '15-15 rule': take about 15 grams of fast-acting carbohydrate (glucose tablets, juice, regular soda), wait 15 minutes, recheck, and repeat if still low. Some people, especially with long-standing diabetes, lose their early warning symptoms ('hypoglycemia unawareness'), which is dangerous and should be discussed with their care team. > **Note:** Educational only. Treatment thresholds and steps should be set with the care team; never adjust insulin or other medication doses on your own. **Sources:** - [Low blood sugar (hypoglycaemia)](https://www.nhs.uk/conditions/low-blood-sugar-hypoglycaemia/) — NHS (UK) - [6. Glycemic Goals and Hypoglycemia (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S128/157561/6-Glycemic-Goals-and-Hypoglycemia-Standards-of) — American Diabetes Association — Diabetes Care, 2025 ### Severe hypoglycemia — a medical emergency **If someone with diabetes becomes unable to swallow, has a seizure, or loses consciousness from low blood sugar, it is an emergency: give glucagon if available and call emergency services.** Severe hypoglycemia is a low blood sugar that a person cannot treat themselves because they are too confused, drowsy, having a seizure, or unconscious. This is a life-threatening emergency. Do NOT put food or drink into the mouth of someone who cannot safely swallow, because of choking risk. Instead, give emergency glucagon if it is available and you are trained — it comes as an injection or a nasal spray and raises blood sugar by prompting the liver to release glucose — and call emergency services (911 in the U.S.) right away. Place an unconscious person on their side. People at risk of severe lows (and those around them) are advised to have a glucagon kit and know how to use it. After any severe low, the episode should be reviewed with the care team to prevent a repeat. > **Note:** If someone is unconscious, having a seizure, or cannot swallow, treat it as an emergency — call emergency services. Do not give food/drink by mouth to someone who can't safely swallow. **Sources:** - [Low blood sugar (hypoglycaemia) — when it's serious](https://www.nhs.uk/conditions/low-blood-sugar-hypoglycaemia/) — NHS (UK) - [6. Glycemic Goals and Hypoglycemia (glucagon, severe hypoglycemia)](https://diabetesjournals.org/care/article/48/Supplement_1/S128/157561/6-Glycemic-Goals-and-Hypoglycemia-Standards-of) — American Diabetes Association — Diabetes Care, 2025 ### Hyperglycemia (high blood sugar) — recognizing it **High blood sugar causes thirst, frequent urination, fatigue, and blurred vision; if it climbs and ketones or severe symptoms appear, it can become an emergency.** Hyperglycemia is blood glucose that is too high. Common causes include too little insulin or medication, illness or infection, stress, steroids, and eating more carbohydrate than the medication covers. Typical symptoms are increased thirst, frequent urination, tiredness, blurred vision, and headaches; these may build over hours to days. Mild, occasional highs are managed by following the care team's plan (hydration, taking medication as prescribed, checking glucose, and looking for a cause). The danger is when hyperglycemia progresses to a crisis — diabetic ketoacidosis (DKA) or the hyperosmolar hyperglycemic state (HHS) — signaled by very high readings, ketones, nausea/vomiting, abdominal pain, rapid breathing, drowsiness, or confusion. Those warning signs mean urgent medical care is needed. **Sources:** - [Hyperglycemia in diabetes — symptoms and causes](https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631) — Mayo Clinic - [Manage Blood Sugar (high blood sugar)](https://www.cdc.gov/diabetes/treatment/index.html) — CDC ### Diabetic ketoacidosis (DKA) — emergency **DKA is a life-threatening buildup of blood acids (ketones) from severe insulin lack, most often in type 1; fruity breath, vomiting, belly pain, and fast breathing are warning signs.** Diabetic ketoacidosis develops when there is not enough insulin for the body to use glucose, so it burns fat instead and produces acidic ketones that build up in the blood. It is most common in type 1 diabetes (and can be the first sign of it) but can occur in type 2 under severe stress; it can also be triggered by missed insulin, infection, or illness, and certain medications (SGLT2 inhibitors) can cause DKA even when glucose is only mildly elevated. Warning signs include high blood sugar and high urine/blood ketones, intense thirst and urination, nausea and vomiting, abdominal pain, weakness, a fruity smell on the breath, rapid deep breathing, and confusion — symptoms can come on within 24 hours. DKA is a medical emergency requiring hospital treatment with fluids, insulin, and electrolytes; untreated, it can be fatal. Anyone with these signs should seek emergency care immediately. > **Note:** DKA is a medical emergency. Suspected DKA — high glucose with ketones, vomiting, abdominal pain, or fast breathing — needs emergency care, not home management. **Sources:** - [Diabetic ketoacidosis — symptoms and causes](https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551) — Mayo Clinic - [Diabetic ketoacidosis](https://www.nhs.uk/conditions/diabetic-ketoacidosis/) — NHS (UK) ### Hyperosmolar hyperglycemic state (HHS) — emergency **HHS is a dangerous emergency of extremely high blood sugar with severe dehydration, mainly in type 2 diabetes, often without significant ketones.** The hyperosmolar hyperglycemic state (HHS) is a serious hyperglycemic emergency seen mostly in type 2 diabetes, often in older adults and frequently triggered by infection, other illness, or missed medication. Blood glucose rises to very high levels (commonly above 600 mg/dL), causing heavy urination that leads to profound dehydration and concentrated ('hyperosmolar') blood. Unlike DKA, there is usually enough insulin to prevent major ketone buildup, so significant acidosis is typically absent — but HHS is at least as dangerous. Symptoms develop over days and include extreme thirst, very frequent urination (then reduced urination as dehydration worsens), weakness, dry mouth, fever, confusion, drowsiness, and eventually loss of consciousness. HHS is a medical emergency requiring hospital treatment with intravenous fluids, insulin, and electrolyte correction; prompt care is essential. > **Note:** HHS is a medical emergency. Very high glucose with confusion, drowsiness, or severe dehydration needs emergency care immediately. **Sources:** - [6. Glycemic Goals and Hypoglycemia — hyperglycemic crises (DKA and HHS)](https://diabetesjournals.org/care/article/48/Supplement_1/S128/157561/6-Glycemic-Goals-and-Hypoglycemia-Standards-of) — American Diabetes Association — Diabetes Care, 2025 - [Diabetic coma — symptoms and causes (HHS, DKA, severe hypoglycemia)](https://www.mayoclinic.org/diseases-conditions/diabetic-coma/symptoms-causes/syc-20371475) — Mayo Clinic ### When a diabetes situation is an emergency **Loss of consciousness, seizure, confusion, persistent vomiting, ketones with high glucose, fast/labored breathing, or inability to keep fluids down all warrant emergency care.** Some diabetes situations need emergency help rather than home management. Call emergency services or go to the ER for: loss of consciousness or a seizure; severe confusion or drowsiness; a low blood sugar that doesn't recover after repeated fast-acting carbohydrate (or where the person can't safely swallow); high blood sugar with moderate-to-large ketones; persistent vomiting or inability to keep fluids down; severe abdominal pain; rapid, deep, or labored breathing; or signs of serious infection in someone with diabetes. During illness, the risk of DKA and HHS rises, which is why having sick-day guidance from the care team matters. When in doubt about whether something is an emergency, it is safer to seek urgent advice — diabetes crises can worsen quickly but respond well to prompt treatment. > **Note:** This is general guidance, not a substitute for emergency services. In a suspected emergency, call your local emergency number. **Sources:** - [Diabetic ketoacidosis — when to see a doctor / emergency](https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551) — Mayo Clinic - [Managing Sick Days (when to get emergency care)](https://www.cdc.gov/diabetes/living-with/managing-sick-days.html) — CDC --- ## Medications & Insulin How diabetes is treated with medicine: insulin types and regimens, and the main non-insulin classes — metformin, GLP-1 receptor agonists, SGLT2 inhibitors, sulfonylureas, DPP-4 inhibitors, and older drugs. ### Types of insulin **Insulins differ by how fast they act and how long they last — rapid, short, intermediate, and long/ultra-long acting — and are combined to mimic the body's natural pattern.** Insulin is essential in type 1 diabetes and used in type 2 when other treatments aren't enough. Insulins are grouped by their action profile. Rapid-acting (e.g. lispro, aspart, glulisine) start working in minutes and are taken at meals to cover food; short-acting 'regular' insulin works a little slower. Intermediate-acting (NPH) lasts roughly half a day. Long-acting and ultra-long-acting 'basal' insulins (e.g. glargine, detemir, degludec) give a steady background level for up to a day or more. Many people use a 'basal-bolus' approach combining a long-acting insulin with mealtime rapid-acting insulin; premixed insulins combine two types in one injection. Insulin is delivered by syringe, pen, or pump. The choice and timing are individualized — and because insulin lowers blood sugar, balancing it against food and activity is what prevents both highs and dangerous lows. > **Note:** Educational overview only — insulin types, doses, and timing are individualized by the prescriber. Never change insulin on your own, and never stop insulin in type 1. **Sources:** - [Insulin, Medicines, & Other Diabetes Treatments](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK - [Type 1 diabetes — insulin (NHS)](https://www.nhs.uk/conditions/type-1-diabetes/) — NHS (UK) ### Insulin regimens and dosing concepts **Common approaches include basal-bolus (background plus mealtime insulin) and pump therapy; dosing aims to match insulin to food, activity, and glucose patterns.** An insulin regimen is the plan for how and when insulin is taken. The most flexible is basal-bolus (multiple daily injections): a once- or twice-daily long-acting basal insulin for background needs, plus rapid-acting bolus insulin at each meal, often calculated from carbohydrate intake and current glucose using an insulin-to-carb ratio and correction factor. Insulin pumps deliver rapid-acting insulin continuously as an adjustable basal rate with mealtime boluses. Simpler regimens (e.g. premixed insulin twice daily) trade flexibility for fewer injections and may suit some people with type 2. Good regimens are built around the person's routine, glucose data, and goals, and are adjusted over time. The core skill — learning how food, activity, illness, and stress move glucose — is taught through diabetes education and supported by the care team. > **Note:** Dosing concepts are educational. Insulin-to-carb ratios, correction factors, and pump settings are set and changed only with the care team. **Sources:** - [Insulin, Medicines, & Other Diabetes Treatments](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK - [Type 1 diabetes in adults: management (NG17)](https://www.nice.org.uk/guidance/ng17) — NICE (UK) ### Metformin **Metformin is the usual first-line pill for type 2 diabetes: it lowers glucose mainly by reducing the liver's glucose output and rarely causes lows on its own.** Metformin (a biguanide) is the most widely used and usually first-choice oral medication for type 2 diabetes. It works chiefly by reducing the amount of glucose the liver releases and improving the body's sensitivity to insulin. It does not stimulate insulin release, so by itself it carries a low risk of hypoglycemia, and it is weight-neutral or modestly weight-reducing. The most common side effects are gastrointestinal (nausea, diarrhea), often eased by taking it with food, starting low, or using an extended-release form. Metformin is generally avoided or dose-adjusted in significant kidney impairment and is paused around certain procedures or serious illness. Decades of use give it a strong safety and cost profile, and it is often continued alongside newer agents. **Sources:** - [Insulin, Medicines, & Other Diabetes Treatments (metformin)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK - [Type 2 diabetes in adults: management (NG28)](https://www.nice.org.uk/guidance/ng28) — NICE (UK) ### GLP-1 receptor agonists (incl. semaglutide, tirzepatide) _(Established)_ **GLP-1 receptor agonists lower glucose, curb appetite, and cause weight loss; some also reduce cardiovascular and kidney risk. Tirzepatide adds a second hormone (GIP) for even greater effect.** GLP-1 receptor agonists mimic the gut hormone GLP-1: they boost insulin release when glucose is high, suppress glucagon, slow stomach emptying, and reduce appetite — lowering blood sugar with little hypoglycemia risk and producing meaningful weight loss. Examples include semaglutide, dulaglutide, and liraglutide, given by injection (semaglutide also in a tablet form). Several have proven cardiovascular benefit, and some reduce progression of kidney disease, so they are favored in people with, or at high risk of, heart or kidney disease. Tirzepatide is a related 'dual agonist' that activates both GIP and GLP-1 receptors; in head-to-head trials it produced greater A1c and weight reduction than semaglutide. Common side effects are gastrointestinal (nausea, vomiting, diarrhea), usually dose-related and easing over time. These drugs are mainly for type 2 diabetes (and obesity), not a replacement for insulin in type 1. **Sources:** - [Insulin, Medicines, & Other Diabetes Treatments (GLP-1)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK - [Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)](https://www.nejm.org/doi/full/10.1056/NEJMoa2107519) — New England Journal of Medicine, 2021 ### SGLT2 inhibitors _(Established)_ **SGLT2 inhibitors make the kidneys excrete excess glucose in urine; beyond lowering blood sugar they protect the heart and kidneys, but carry specific risks like genital infections and rare DKA.** SGLT2 inhibitors (e.g. empagliflozin, dapagliflozin, canagliflozin) block a kidney transporter that reabsorbs glucose, so excess glucose is passed out in the urine. They lower glucose with low hypoglycemia risk and cause modest weight and blood-pressure reduction. Major trials show they reduce hospitalization for heart failure and slow the progression of chronic kidney disease — benefits so significant that some are now used for heart failure and kidney disease even in people without diabetes. Risks to know about include genital yeast and urinary infections, dehydration, and a rare but serious form of diabetic ketoacidosis that can occur with near-normal glucose ('euglycemic DKA'), which is why they are typically paused during serious illness, fasting, or around surgery. They are mainly used in type 2 diabetes. > **Note:** SGLT2 inhibitors can cause ketoacidosis even with only mildly raised glucose; sudden illness, vomiting, or ketones while taking one warrants urgent medical advice. **Sources:** - [Insulin, Medicines, & Other Diabetes Treatments (SGLT2)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK - [Type 2 diabetes in adults: management (NG28)](https://www.nice.org.uk/guidance/ng28) — NICE (UK) ### Sulfonylureas and meglitinides **These older pills push the pancreas to release more insulin; they are effective and inexpensive but can cause low blood sugar and modest weight gain.** Sulfonylureas (e.g. glipizide, gliclazide, glimepiride) and the shorter-acting meglitinides (e.g. repaglinide) lower glucose by stimulating the beta cells to secrete more insulin regardless of the current glucose level. Because they raise insulin directly, they are among the oral agents most likely to cause hypoglycemia — a particular concern in older adults, those with irregular meals, or kidney impairment — and they tend to cause slight weight gain. They remain useful where cost or access matters and work quickly, but newer classes (GLP-1 agonists, SGLT2 inhibitors) are often preferred when heart/kidney protection or weight loss is a priority. Notably, certain monogenic (MODY/neonatal) diabetes subtypes respond especially well to sulfonylureas, sometimes allowing people to stop insulin. > **Note:** Sulfonylureas and meglitinides can cause hypoglycemia — recognizing and treating lows matters, and dose changes belong with the prescriber. **Sources:** - [Insulin, Medicines, & Other Diabetes Treatments (sulfonylureas)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK - [Type 2 diabetes in adults: management (NG28)](https://www.nice.org.uk/guidance/ng28) — NICE (UK) ### DPP-4 inhibitors, thiazolidinediones, and other agents **Other type 2 options include DPP-4 inhibitors (mild, weight-neutral, low-hypo risk), pioglitazone (improves insulin sensitivity), and older drugs like acarbose.** Several additional classes round out type 2 treatment. DPP-4 inhibitors (e.g. sitagliptin, linagliptin) raise the body's own incretin hormones modestly; they are weight-neutral, well tolerated, and carry low hypoglycemia risk, but their glucose-lowering and outcome benefits are smaller than GLP-1 agonists or SGLT2 inhibitors (and they aren't combined with GLP-1 agonists). Thiazolidinediones (pioglitazone) improve insulin sensitivity and durably lower glucose but can cause fluid retention, weight gain, and increased fracture risk, limiting use. Alpha-glucosidase inhibitors (acarbose) slow carbohydrate absorption in the gut, blunting post-meal spikes, at the cost of flatulence. Amylin analogs (pramlintide) are an injectable mealtime add-on used by some people with insulin-treated diabetes. The 'right' combination is chosen for each person based on glucose targets, weight, heart/kidney status, hypoglycemia risk, side effects, and cost. **Sources:** - [Insulin, Medicines, & Other Diabetes Treatments (other classes)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK - [Type 2 diabetes in adults: management (NG28)](https://www.nice.org.uk/guidance/ng28) — NICE (UK) --- ## Devices & Technology The tools of modern diabetes management: fingerstick meters, continuous glucose monitors (CGM), insulin pumps, and automated insulin delivery (closed-loop) systems. ### Blood glucose meters (fingerstick testing) **A glucose meter reads a drop of blood from a fingertip, giving a snapshot of blood sugar at that moment — still a core tool and a backup to CGM.** A blood glucose meter measures glucose in a small drop of blood, usually from a fingertip prick onto a test strip. It gives an accurate single-point reading and remains fundamental: it guides mealtime and correction decisions for many people, confirms suspected highs or lows, and serves as a backup when a CGM reading doesn't match how someone feels. Typical target ranges many adults aim for are about 80–130 mg/dL before meals and under 180 mg/dL about two hours after starting a meal, though individual targets vary. How often to check depends on the treatment: people on intensive insulin may test several times a day (or rely mainly on CGM), while those on lower-risk medications test less. Technique, strip storage, and meter calibration all affect accuracy. **Sources:** - [Manage Blood Sugar (checking blood sugar)](https://www.cdc.gov/diabetes/treatment/index.html) — CDC - [Insulin, Medicines, & Other Diabetes Treatments (monitoring)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK ### Continuous glucose monitoring (CGM) _(Established)_ **A CGM uses a tiny under-skin sensor to read glucose every few minutes, showing trends, direction arrows, and alerts for highs and lows.** A continuous glucose monitor (CGM) measures glucose in the fluid just under the skin via a small sensor worn for days to weeks, sending readings every few minutes to a phone, receiver, or pump. Beyond single numbers, CGM shows the direction and speed of glucose change and can alert the user before a dangerous high or low — especially valuable for people on insulin and those with hypoglycemia unawareness. CGM data also produce 'time in range' (the percentage of time glucose stays within target), an increasingly used measure alongside A1c. Some systems are 'real-time' with continuous alerts; others are 'intermittently scanned' (the user scans the sensor). CGM has been shown to improve glucose control and reduce hypoglycemia, and it is the backbone of automated insulin delivery systems. **Sources:** - [Insulin, Medicines, & Other Diabetes Treatments (CGM, artificial pancreas)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK - [Automated Insulin Delivery Systems and Insulin Pumps (CGM role)](https://www.breakthrought1d.org/daily-management/t1d-technology/aid-insulin-pumps/) — Breakthrough T1D (formerly JDRF) ### Insulin pumps **An insulin pump delivers rapid-acting insulin continuously through a small under-skin cannula, replacing multiple daily injections with adjustable basal rates and mealtime boluses.** An insulin pump is a small device that delivers rapid-acting insulin through a thin tube and cannula inserted under the skin (or via a tubeless 'patch' pump worn on the body). Instead of separate long- and rapid-acting injections, the pump provides a steady, programmable 'basal' trickle of insulin throughout the day plus user-requested 'bolus' doses for meals and corrections. Pumps allow fine, flexible adjustments — different basal rates at different times, temporary rates for exercise or illness — and can integrate with CGM. They require training and active engagement: site changes every few days, carbohydrate counting, and troubleshooting, since an interruption in delivery can lead to rapid glucose rise and ketosis. Pumps are used mainly in type 1 diabetes and in some insulin-treated type 2. **Sources:** - [Automated Insulin Delivery Systems and Insulin Pumps](https://www.breakthrought1d.org/daily-management/t1d-technology/aid-insulin-pumps/) — Breakthrough T1D (formerly JDRF) - [Insulin, Medicines, & Other Diabetes Treatments (insulin pumps)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK ### Automated insulin delivery (closed-loop / artificial pancreas) _(Established)_ **AID systems link a CGM, an insulin pump, and an algorithm so insulin is adjusted automatically — improving time in range and reducing lows, though they still need user input for meals.** Automated insulin delivery (AID) — also called closed-loop or 'artificial pancreas' systems — combines three parts: a continuous glucose monitor, an insulin pump, and a control algorithm that automatically adjusts insulin delivery based on real-time and predicted glucose. Most approved systems are 'hybrid' closed loops: they automate background insulin and corrections but still ask the user to announce meals and bolus for carbohydrates. Clinical studies show AID systems improve time in range and reduce hypoglycemia compared with pump-plus-CGM without automation, and they ease the relentless mental load of diabetes. Several FDA-cleared systems exist, and the field is moving toward fuller automation and simpler meal handling. AID is a major advance but not a cure — it still depends on working hardware, accurate sensors, and an engaged user. **Sources:** - [Automated Insulin Delivery Systems and Insulin Pumps](https://www.breakthrought1d.org/daily-management/t1d-technology/aid-insulin-pumps/) — Breakthrough T1D (formerly JDRF) - [Insulin, Medicines, & Other Diabetes Treatments (artificial pancreas systems)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK --- ## Key Drug Interactions Educational overview of interactions that matter for common diabetes medicines — compounded hypoglycemia (alcohol, beta-blockers, certain antibiotics), SGLT2 + diuretic and metformin + contrast/renal cautions, and drugs that raise glucose. Always have a pharmacist or clinician check actual combinations. ### How to think about diabetes drug interactions **Interactions are common with diabetes medicines, but whether one matters depends on the person; the safe move is to keep one full med-and-supplement list and have a pharmacist or clinician check it — not to self-judge 'safe' or 'unsafe.'** People with diabetes often take several medicines, and many interact with diabetes drugs — some raising the risk of low blood sugar, some reducing glucose control, some affecting the kidneys or hydration. The entries here explain the best-known interactions so a person can recognize them and ask about them, but they are not a substitute for an authoritative check. Whether a given combination is a problem depends on the individual's kidney function, other conditions, doses, and timing — which is exactly the judgment a pharmacist or prescriber is trained to make. Practical habits that genuinely reduce risk: keep one up-to-date list of every prescription, over-the-counter product, vitamin, and herbal supplement; show it at every appointment and to the pharmacist with each new prescription; use one pharmacy where possible so interactions are screened automatically; and ask specifically 'does this interact with my diabetes medicines?' before starting anything new. Never treat any entry here as a definitive ruling. > **Note:** Educational only — not an interaction check. Have a pharmacist or clinician review your actual medications and supplements; this is never a definitive safe/unsafe ruling. **Sources:** - [9. Pharmacologic Approaches to Glycemic Treatment (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S181/157569/9-Pharmacologic-Approaches-to-Glycemic-Treatment) — American Diabetes Association — Diabetes Care, 2025 - [Diabetes and Dietary Supplements (interactions caution)](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements) — NIH / NCCIH ### Things that compound hypoglycemia _(Established)_ **With insulin or sulfonylureas, alcohol, other glucose-lowering agents, and certain antibiotics can deepen lows; combining glucose-lowering drugs multiplies the risk.** The drugs most likely to cause hypoglycemia are insulin and the insulin-stimulating sulfonylureas/meglitinides, and several things can compound their effect. Alcohol is a major one: it suppresses the liver's release of glucose and can cause delayed lows hours later, including overnight, with warning signs easily mistaken for intoxication. Combining glucose-lowering agents (for example adding insulin to a sulfonylurea, or stacking multiple agents) raises hypoglycemia risk and often calls for dose review. Some medications potentiate sulfonylureas or otherwise lower glucose — examples discussed in the literature include certain antibiotics (such as fluoroquinolones and sulfamethoxazole-trimethoprim) and some others — which is why a new prescription is a good moment for an interaction check. Reduced food intake, kidney impairment (which prolongs some drugs), and increased activity add to the effect. The takeaway is awareness and monitoring, with any dose adjustments made by the prescriber. > **Note:** Do not adjust insulin or sulfonylurea doses yourself for alcohol or a new medicine — ask the prescriber or pharmacist. Lows from alcohol can be delayed and severe. **Sources:** - [6. Glycemic Goals and Hypoglycemia (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S128/157561/6-Glycemic-Goals-and-Hypoglycemia-Standards-of) — American Diabetes Association — Diabetes Care, 2025 - [Low blood sugar (hypoglycaemia) — alcohol and causes](https://www.nhs.uk/conditions/low-blood-sugar-hypoglycaemia/) — NHS (UK) ### Beta-blockers can mask hypoglycemia warning signs _(Established)_ **Beta-blockers (often prescribed for heart disease or blood pressure) can blunt the adrenaline-driven warning symptoms of a low — like shakiness and a racing heart — so a low may be felt less clearly.** Many of the early warning symptoms of hypoglycemia — trembling, palpitations, anxiety — are produced by the surge of adrenaline the body releases as glucose falls. Beta-blockers, commonly used for high blood pressure, angina, heart failure, and after a heart attack, blunt these adrenergic symptoms, so a person on a beta-blocker may notice a low later or less clearly (sweating, which is driven differently, often still occurs). Non-selective beta-blockers can also slightly impair the body's glucose-recovery response. This does not mean beta-blockers are 'unsafe' with diabetes — they are important, life-saving drugs for many people with the heart disease that so often accompanies diabetes — but it is a reason for extra vigilance: relying more on glucose monitoring (especially CGM) rather than symptoms, and being aware that hypoglycemia unawareness may be more likely. The benefit-versus-risk balance and any monitoring plan are decisions for the care team. > **Note:** Don't stop a beta-blocker on your own — they treat serious heart conditions. If you take one, discuss hypoglycemia monitoring with your care team. **Sources:** - [6. Glycemic Goals and Hypoglycemia (hypoglycemia symptoms and awareness)](https://diabetesjournals.org/care/article/48/Supplement_1/S128/157561/6-Glycemic-Goals-and-Hypoglycemia-Standards-of) — American Diabetes Association — Diabetes Care, 2025 - [10. Cardiovascular Disease and Risk Management (beta-blocker use in diabetes)](https://diabetesjournals.org/care/article/48/Supplement_1/S207/157549/10-Cardiovascular-Disease-and-Risk-Management) — American Diabetes Association — Diabetes Care, 2025 ### Metformin: kidney function, dehydration, and contrast dye _(Established)_ **Metformin is cleared by the kidneys, so it is paused around imaging with contrast dye, serious illness, dehydration, or surgery to lower the rare risk of lactic acidosis.** Metformin is removed from the body by the kidneys, so situations that suddenly reduce kidney function can let it accumulate and, rarely, contribute to a serious condition called lactic acidosis. For that reason metformin is commonly paused around events that stress the kidneys: imaging procedures that use iodinated contrast dye (such as some CT scans and angiograms), major surgery, and acute illnesses with dehydration, vomiting, or diarrhea — and it is generally avoided or dose-limited when kidney function is significantly reduced. It is usually restarted once kidney function is confirmed stable. People taking metformin are often advised to hold it during 'sick days' with significant dehydration and to mention they take it before any scan or procedure. These are standard precautions, not a sign metformin is dangerous — it has an excellent long-term safety record — but the timing of holding and restarting should be confirmed with the clinician, pharmacist, or the team doing the procedure. > **Note:** Tell the team before any scan with contrast or surgery that you take metformin, and confirm when to stop and restart it — don't guess. **Sources:** - [Metformin — cautions, kidney function and procedures](https://www.nhs.uk/medicines/metformin/) — NHS (UK) - [Insulin, Medicines, & Other Diabetes Treatments (metformin and kidneys)](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) — NIH / NIDDK ### SGLT2 inhibitors: diuretics, dehydration, and DKA risk _(Established)_ **SGLT2 inhibitors increase urination, so combined with diuretics or illness they can cause dehydration and low blood pressure; they are also paused around surgery and illness because of a rare ketoacidosis risk.** SGLT2 inhibitors work by making the kidneys excrete glucose in the urine, which also increases water loss. Combined with diuretics ('water pills'), or during illness with poor fluid intake, this can lead to dehydration, low blood pressure, dizziness on standing, and kidney stress, so clinicians sometimes review diuretic doses when starting them and advise attention to hydration. Separately, SGLT2 inhibitors carry a rare but serious risk of diabetic ketoacidosis that can occur even with near-normal glucose ('euglycemic DKA'), particularly during fasting, dehydration, acute illness, very low-carbohydrate intake, surgery, or sharp insulin reductions. For that reason they are typically paused before planned surgery and during significant acute illness, and ketones should be checked if a person feels unwell even when glucose is not high. These cautions make the medicine safer to use, not unsafe — but the specifics of when to hold and restart, and how they fit with diuretics, belong with the prescriber and pharmacist. > **Note:** Feeling unwell on an SGLT2 inhibitor — even with normal glucose — warrants checking ketones and seeking advice; confirm with the team when to pause it for illness or surgery. **Sources:** - [9. Pharmacologic Approaches to Glycemic Treatment (SGLT2 inhibitor cautions)](https://diabetesjournals.org/care/article/48/Supplement_1/S181/157569/9-Pharmacologic-Approaches-to-Glycemic-Treatment) — American Diabetes Association — Diabetes Care, 2025 - [Diabetic ketoacidosis — causes (including medication-related)](https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551) — Mayo Clinic ### Medications that can raise blood glucose _(Established)_ **Some commonly used drugs — especially steroids, and also certain antipsychotics, some diuretics, and others — can raise blood glucose and may temporarily need closer monitoring or treatment changes.** Several widely used medications can push blood glucose up, sometimes substantially. Glucocorticoids (steroids such as prednisone, whether as tablets, injections, or sometimes inhaled/topical at high doses) are the classic example and can cause marked, often predictable rises, especially later in the day. Other agents associated with higher glucose include some antipsychotics (notably olanzapine and clozapine), thiazide diuretics (usually modestly), certain immunosuppressants, some HIV medicines, and others. This does not mean these drugs are off-limits in diabetes — they may be essential — but starting them is a reason to monitor glucose more closely and, sometimes, to temporarily intensify diabetes treatment, with the changes planned and then reversed by the care team as the other medicine is adjusted or stopped. Knowing that a new drug can raise glucose helps a person watch for it and report unexpected highs rather than assuming their diabetes has simply worsened. **Sources:** - [4. Comprehensive Medical Evaluation and Assessment of Comorbidities (medications affecting glucose)](https://diabetesjournals.org/care/article/48/Supplement_1/S59/157568/4-Comprehensive-Medical-Evaluation-and-Assessment) — American Diabetes Association — Diabetes Care, 2025 - [Hyperglycemia in diabetes — contributing factors](https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631) — Mayo Clinic ### Over-the-counter products and supplements _(Established)_ **OTC remedies and supplements can interact too — some 'blood sugar' supplements add to glucose-lowering (hypoglycemia risk), NSAIDs can stress the kidneys alongside diabetes drugs, and some cold remedies affect glucose.** Interactions are not limited to prescriptions. Dietary supplements marketed for blood sugar (such as berberine or alpha-lipoic acid) can add to the glucose-lowering effect of diabetes medicines and raise the risk of hypoglycemia, and some have their own drug interactions — yet they are often taken without telling the care team. Common over-the-counter medicines matter too: nonsteroidal anti-inflammatory drugs (NSAIDs like ibuprofen) can stress the kidneys, a particular concern alongside SGLT2 inhibitors, metformin, and blood-pressure drugs (ACE inhibitors/ARBs) used in diabetes. Some cold and flu products contain sugars or decongestants that can nudge glucose up, and certain remedies interact with other medicines a person takes. Because supplements and OTC products are easy to start without a prescription screen, they are exactly where interactions get missed — so the same rule applies: list them, and run anything new past a pharmacist who can check it against the full regimen. > **Note:** 'Natural' supplements and everyday OTC medicines can still interact — check with a pharmacist before adding them to diabetes treatment. **Sources:** - [Diabetes and Dietary Supplements (interactions and hypoglycemia risk)](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements) — NIH / NCCIH - [4. Comprehensive Medical Evaluation and Assessment of Comorbidities (medication reconciliation)](https://diabetesjournals.org/care/article/48/Supplement_1/S59/157568/4-Comprehensive-Medical-Evaluation-and-Assessment) — American Diabetes Association — Diabetes Care, 2025 --- ## Therapy & Lifestyle The lifestyle foundations of diabetes management: nutrition, carbohydrate counting, exercise, weight management, the evidence for putting type 2 diabetes into remission, and structured self-management education. ### Medical nutrition therapy _(Established)_ **There is no single 'diabetes diet'; evidence supports several eating patterns, individualized with a dietitian, that emphasize whole foods and manage carbohydrate quality and quantity.** Nutrition is central to managing every type of diabetes, but research shows no one diet fits everyone. Several eating patterns can work — Mediterranean-style, lower-carbohydrate, plant-based, and others — when they are individualized to a person's preferences, culture, goals, and other health conditions. Shared principles include favoring non-starchy vegetables, whole grains, legumes, fruit, nuts, and lean proteins; limiting refined carbohydrate, sugary drinks, and ultra-processed foods; and paying attention to both the amount and type of carbohydrate, since carbohydrate has the largest direct effect on blood glucose. Working with a registered dietitian for medical nutrition therapy improves outcomes and is recommended as part of standard care. For people on mealtime insulin, matching insulin to carbohydrate intake (carb counting) is a key skill. **Sources:** - [Diabetes Diet, Eating, & Physical Activity](https://www.niddk.nih.gov/health-information/diabetes/overview/diet-eating-physical-activity) — NIH / NIDDK - [5. Facilitating Positive Health Behaviors and Well-being (nutrition)](https://diabetesjournals.org/care/issue/48/Supplement_1) — American Diabetes Association — Diabetes Care, 2025 ### Carbohydrate counting **Carb counting estimates the carbohydrate in meals so mealtime insulin can be matched to food — a core skill for insulin users, especially in type 1.** Because carbohydrate raises blood glucose more than protein or fat, estimating the carbohydrate content of meals helps people on mealtime insulin dose accurately. In its fuller form, carb counting pairs a meal's grams of carbohydrate with an individualized insulin-to-carbohydrate ratio to calculate the bolus, often combined with a correction dose based on current glucose. It allows flexible eating rather than fixed meals. Even without insulin, being aware of carbohydrate portions helps manage post-meal glucose. Carb counting is usually taught by a diabetes educator or dietitian and refined using glucose data over time. Like all dosing skills, the ratios and correction factors are set with the care team, and CGM trends help fine-tune how well meals are being covered. > **Note:** Insulin-to-carb ratios and correction doses are individualized and set with the care team — this is educational background, not a dosing instruction. **Sources:** - [Carbohydrate Counting & Diabetes](https://www.niddk.nih.gov/health-information/diabetes/overview/healthy-living-with-diabetes) — NIH / NIDDK ### Physical activity and exercise _(Established)_ **Regular activity improves insulin sensitivity and glucose control, supports weight and heart health; insulin users need to plan for exercise-related lows.** Physical activity is a cornerstone of diabetes care. Exercise makes muscles take up glucose and improves insulin sensitivity for hours afterward, lowering blood glucose and supporting weight, blood pressure, cholesterol, mood, and cardiovascular health. General guidance for many adults is about 150 minutes a week of moderate aerobic activity spread across the week, plus muscle-strengthening on two or more days, and reducing prolonged sitting — adjusted to ability and other health conditions. For people on insulin or sulfonylureas, activity can cause hypoglycemia during or even many hours later, so planning matters: checking glucose, adjusting food or (with the care team) medication, and carrying fast-acting carbohydrate. In some situations — very high glucose with ketones, or certain eye or foot complications — specific precautions apply, which is why an individualized plan is best. **Sources:** - [Diabetes Diet, Eating, & Physical Activity](https://www.niddk.nih.gov/health-information/diabetes/overview/diet-eating-physical-activity) — NIH / NIDDK - [Manage Blood Sugar (physical activity)](https://www.cdc.gov/diabetes/treatment/index.html) — CDC ### Weight management in type 2 diabetes _(Established)_ **For people with type 2 and excess weight, losing weight improves glucose control and cardiovascular risk; larger sustained losses can be transformative.** Because excess body fat — especially in the liver and abdomen — drives the insulin resistance behind type 2 diabetes, weight management is one of the most powerful levers in its care. Even modest weight loss (around 5%) improves blood glucose, blood pressure, and cholesterol, and larger sustained losses bring proportionally greater benefit, including the possibility of remission. Approaches include structured lifestyle programs (nutrition plus activity), and increasingly the GLP-1 and dual GIP/GLP-1 medications that produce substantial weight loss. Metabolic (bariatric) surgery can lead to major, durable weight loss and high rates of diabetes remission in eligible people with obesity. Weight management is framed not as willpower but as treatment of the underlying biology, individualized and supported by the care team. **Sources:** - [8. Obesity and Weight Management (Standards of Care 2025)](https://diabetesjournals.org/care/issue/48/Supplement_1) — American Diabetes Association — Diabetes Care, 2025 - [Type 2 diabetes — managing weight (NHS)](https://www.nhs.uk/conditions/type-2-diabetes/) — NHS (UK) ### Type 2 diabetes remission _(Good evidence)_ **Strong evidence shows substantial weight loss can put type 2 diabetes into remission — normal blood glucose without glucose-lowering medication — for many people, especially earlier in the disease.** Remission of type 2 diabetes means A1c stays below the diabetes threshold (generally under 6.5%) for at least three months without glucose-lowering medication. It is now well supported by evidence. The landmark DiRECT trial used a structured low-calorie diet to achieve weight loss in primary care: nearly half of participants were in remission at one year, with remission strongly tied to the amount of weight lost (around nine in ten of those losing 15 kg or more), and a meaningful share sustained it at two and five years. Remission is most achievable earlier in the disease and with greater, sustained weight loss, achieved through intensive diet programs, sometimes medication, or metabolic surgery. It is not a permanent cure — diabetes can return, especially if weight is regained — so ongoing monitoring continues. Remission is realistic for many but not everyone, and is pursued with the care team. **Sources:** - [Primary care-led weight management for remission of type 2 diabetes (DiRECT)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33102-1/fulltext) — The Lancet, 2018 - [What is type 2 diabetes remission?](https://www.diabetes.org.uk/about-diabetes/type-2-diabetes/remission/what-is-type-2-diabetes-remission) — Diabetes UK ### Diabetes self-management education and support (DSMES) _(Established)_ **Structured education programs teach the skills of daily diabetes management and are linked to better glucose control, fewer complications, and improved wellbeing.** Diabetes is largely self-managed day to day, so learning the skills is itself a treatment. Diabetes self-management education and support (DSMES) — delivered by diabetes educators, nurses, dietitians, and pharmacists — covers monitoring, medication and insulin use, nutrition, activity, problem-solving for highs and lows, sick-day rules, foot and eye care, and coping. Evidence links structured education to better glucose control, lower risk of complications, and improved quality of life and confidence. Key moments to seek (or revisit) education include at diagnosis, when not meeting goals, when complications or life changes arise, and when transitioning care. Programs are tailored to the diabetes type and the person's circumstances, and ongoing support — not just a one-time class — produces the best results. **Sources:** - [5. Facilitating Positive Health Behaviors and Well-being (DSMES)](https://diabetesjournals.org/care/issue/48/Supplement_1) — American Diabetes Association — Diabetes Care, 2025 - [Managing Diabetes (education and self-care)](https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes) — NIH / NIDDK --- ## Patient Care & Self-Management Day-to-day care that protects long-term health: foot care, eye/kidney/nerve screening, cardiovascular risk management, sick-day rules, driving safety, and looking after mental health. ### Foot care **Diabetes can damage nerves and circulation in the feet, so daily checks, good footwear, and prompt attention to any sore can prevent serious problems including amputation.** Foot problems are common and potentially serious in diabetes because nerve damage (neuropathy) can blunt the ability to feel injury, and poor circulation slows healing — so a small blister, cut, or pressure sore can progress to an ulcer or infection before it is noticed. Daily self-care greatly reduces this risk: check the feet every day (including the soles, using a mirror or a helper if needed) for cuts, blisters, redness, swelling, or nail problems; wash and dry them carefully, especially between the toes; moisturize dry skin but not between the toes; never go barefoot; wear well-fitting shoes and check inside them before putting them on; and keep toenails trimmed safely. A foot examination by a clinician at least yearly (more often if there is neuropathy or prior ulcers) is recommended, and any non-healing sore, spreading redness, or new numbness should be reported promptly. > **Note:** A non-healing foot sore, spreading redness, or new numbness needs prompt medical attention — foot infections can escalate quickly in diabetes. **Sources:** - [Diabetes & Foot Problems](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/foot-problems) — NIH / NIDDK ### Eye and retinopathy screening **Diabetic eye disease often has no early symptoms, so regular dilated eye exams are essential to catch and treat retinopathy before vision is lost.** Diabetes can damage the small blood vessels of the retina (diabetic retinopathy) and cause macular edema, glaucoma, and cataracts. Early retinopathy usually causes no symptoms, and by the time vision changes appear, damage may be advanced — yet it is a leading, and largely preventable, cause of blindness. The key is regular screening: a dilated eye examination (or approved retinal imaging) on a schedule set by the eye/care team, typically starting at diagnosis for type 2, within a few years of onset for type 1, and during pregnancy. Detected early, retinopathy can be treated (laser, injections of anti-VEGF medication, or surgery) to preserve sight. Keeping blood glucose, blood pressure, and cholesterol in target ranges substantially lowers the risk and slows progression. Sudden vision changes, floaters, or vision loss warrant urgent eye review. **Sources:** - [Diabetic Eye Disease](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-eye-disease) — NIH / NIDDK ### Kidney monitoring **Diabetes is the leading cause of kidney disease; yearly urine and blood tests catch it early, when treatment can slow or prevent progression.** Diabetic kidney disease develops when high glucose (often alongside high blood pressure) damages the kidneys' filtering units over years. It is the leading cause of kidney failure, yet it is silent in its early stages, which makes monitoring vital. Recommended tests are a urine check for albumin (the urine albumin-to-creatinine ratio, which detects small amounts of protein leaking into urine) and a blood test for kidney function (estimated GFR), typically at least yearly. Catching kidney disease early allows protective treatment: tight blood pressure and glucose control, and medications that protect the kidneys — ACE inhibitors or ARBs, SGLT2 inhibitors, and certain others — that can slow progression and reduce cardiovascular risk. Avoiding kidney-stressing factors (such as some pain medicines and dehydration during illness) also helps. **Sources:** - [Diabetic Kidney Disease](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease) — NIH / NIDDK ### Nerve damage (neuropathy) monitoring **Diabetic neuropathy can affect the feet, digestion, heart rate, and more; regular checks and good glucose control help detect and limit it.** High glucose over time can damage nerves throughout the body. The most common form, peripheral neuropathy, affects the feet and legs (and later hands), causing numbness, tingling, burning, or pain, and raising the risk of unnoticed foot injuries. Autonomic neuropathy affects nerves controlling internal functions, leading to problems such as digestive issues (including delayed stomach emptying, or gastroparesis), bladder problems, sexual dysfunction, abnormal sweating, and blunted heart-rate and blood-pressure responses — the latter can also mask the warning signs of hypoglycemia. Monitoring includes regular foot sensation checks and reporting new symptoms. Management focuses on keeping glucose, blood pressure, and lipids in range to slow progression, foot protection, and treating symptoms (for example, specific medications for neuropathic pain). Early attention can prevent complications like foot ulcers and falls. **Sources:** - [What Is Diabetic Neuropathy?](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies/what-is-diabetic-neuropathy) — NIH / NIDDK ### Heart and blood-vessel risk management **Diabetes raises the risk of heart attack and stroke, so care targets not just glucose but also blood pressure, cholesterol, and smoking.** Cardiovascular disease — heart attack, stroke, and peripheral artery disease — is the leading cause of death in diabetes, because high glucose accelerates damage to blood vessels. Good diabetes care therefore looks well beyond glucose to the whole cardiovascular risk picture, sometimes summarized as the 'ABCs': A1c (glucose), Blood pressure, Cholesterol, and Stopping smoking. Managing blood pressure (often with ACE inhibitors or ARBs), lowering LDL cholesterol (commonly with statins), not smoking, staying active, and eating well all substantially reduce heart and stroke risk. For people with established cardiovascular or kidney disease, certain glucose medications (GLP-1 receptor agonists and SGLT2 inhibitors) are chosen specifically because they reduce cardiovascular events and heart-failure hospitalization. Aspirin is used in some, but only when the care team judges the benefit outweighs bleeding risk. **Sources:** - [Preventing Diabetes Problems (heart disease and stroke)](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems) — NIH / NIDDK - [Manage Blood Sugar and risk factors (ABCs)](https://www.cdc.gov/diabetes/treatment/index.html) — CDC ### Sick-day rules **Illness raises blood sugar and the risk of DKA/HHS; sick-day plans usually mean keep taking diabetes medication, check glucose (and ketones) more often, stay hydrated, and know when to call.** Being unwell — even with a cold, flu, or stomach bug — stresses the body, raises glucose, and increases the risk of a hyperglycemic emergency, so people with diabetes benefit from a 'sick-day' plan agreed in advance with their care team. General principles: keep taking insulin and most diabetes medicines, even if eating less (do not simply stop insulin in type 1 — stopping it is a common cause of DKA); check blood glucose more often, and check ketones if glucose is high or you have type 1; drink plenty of fluids to prevent dehydration; try to keep taking in some carbohydrate. Certain medicines (such as SGLT2 inhibitors and sometimes metformin) may be paused during acute illness on medical advice. Seek urgent help for persistent vomiting, inability to keep fluids down, moderate-to-large ketones, very high or hard-to-control glucose, or signs of DKA/HHS. Having a written plan and emergency contacts ready makes sick days safer. > **Note:** Sick-day plans are individualized. In type 1, do not stop insulin during illness; confirm any medication pauses (e.g. SGLT2 inhibitors) with the care team, and seek urgent help for ketones or persistent vomiting. **Sources:** - [Managing Sick Days](https://www.cdc.gov/diabetes/living-with/managing-sick-days.html) — CDC ### Driving and hypoglycemia safety **For people on insulin or sulfonylureas, low blood sugar can impair driving; checking glucose before and during longer drives and carrying carbohydrate keeps driving safe.** Driving is generally safe for people with well-managed diabetes, but hypoglycemia is a real hazard because it can impair concentration, judgment, and reaction time. The main precautions apply to those on insulin or other medications that can cause lows: check glucose before driving and at intervals on longer journeys, don't drive if glucose is low or you feel hypo symptoms (treat first, then wait until recovered), keep fast-acting carbohydrate and a meter/CGM within reach, and never start a long drive on a falling or borderline glucose. People with hypoglycemia unawareness, recent severe lows, or significant eye complications may have specific restrictions, and many jurisdictions have licensing rules for drivers with diabetes. Discussing driving safety with the care team — and knowing local regulations — helps people keep driving while protecting themselves and others. **Sources:** - [6. Glycemic Goals and Hypoglycemia (hypoglycemia and driving)](https://diabetesjournals.org/care/article/48/Supplement_1/S128/157561/6-Glycemic-Goals-and-Hypoglycemia-Standards-of) — American Diabetes Association — Diabetes Care, 2025 - [Low blood sugar (hypoglycaemia) — driving](https://www.nhs.uk/conditions/low-blood-sugar-hypoglycaemia/) — NHS (UK) ### Mental health and diabetes distress **The relentless demands of diabetes commonly affect mood; 'diabetes distress,' depression, and anxiety are real, treatable, and part of good diabetes care.** Diabetes asks for constant attention — monitoring, dosing, food decisions, and worry about complications — and that load takes an emotional toll. 'Diabetes distress' (feeling overwhelmed, frustrated, or burned out by diabetes) is very common and distinct from clinical depression, though the two can overlap; depression and anxiety also occur more often in people with diabetes and can worsen self-care and glucose control. Eating disorders, including unsafe insulin restriction, are a particular risk and need specialized help. These are recognized, treatable parts of diabetes care, not personal failings: guidelines recommend periodic screening for distress, depression, and anxiety, and connecting people with counseling, peer support, diabetes education, and mental health treatment when needed. Addressing the emotional side often improves both wellbeing and glucose outcomes. **Sources:** - [5. Facilitating Positive Health Behaviors and Well-being (psychosocial care)](https://diabetesjournals.org/care/issue/48/Supplement_1) — American Diabetes Association — Diabetes Care, 2025 - [Managing Diabetes (mental health and coping)](https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes) — NIH / NIDDK --- ## Chronic Complications The long-term complications of diabetes: microvascular disease (retinopathy, nephropathy, neuropathy), macrovascular disease (heart attack, stroke, peripheral artery disease), and why glucose control prevents them. ### Why long-term complications develop **Years of high glucose damage blood vessels large and small; this underlies most diabetes complications and is why long-term control matters.** Most chronic complications of diabetes stem from damage to blood vessels caused by prolonged high glucose, often compounded by high blood pressure and abnormal cholesterol. The damage is grouped into two categories. 'Microvascular' disease affects the smallest vessels and causes the classic diabetes complications of the eyes (retinopathy), kidneys (nephropathy), and nerves (neuropathy). 'Macrovascular' disease affects large arteries, accelerating atherosclerosis and raising the risk of heart attack, stroke, and peripheral artery disease. Landmark studies established that keeping glucose closer to normal substantially lowers the risk of microvascular complications, and that managing blood pressure, cholesterol, and smoking is essential to reduce macrovascular risk. The encouraging message is that complications are not inevitable — good, sustained management greatly reduces them. **Sources:** - [Preventing Diabetes Problems](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems) — NIH / NIDDK - [Diabetes Basics — complications](https://www.cdc.gov/diabetes/about/index.html) — CDC ### Diabetic retinopathy and eye disease **Damage to the retina's blood vessels is a leading cause of blindness in adults, but is preventable and treatable when caught early through screening.** Diabetic retinopathy is damage to the blood vessels of the light-sensing retina. Early ('non-proliferative') retinopathy may cause vessels to leak or close; advanced ('proliferative') retinopathy involves fragile new vessels that can bleed and lead to retinal detachment. Diabetic macular edema — fluid in the central retina — can blur vision at any stage. Diabetes also raises the risk of cataracts and glaucoma. Because early disease is symptomless, regular dilated eye exams are the key to catching it before vision is threatened. Treatments — laser photocoagulation, anti-VEGF injections, and surgery — are effective at preserving sight when started in time, and tight control of glucose, blood pressure, and lipids slows progression. Diabetic eye disease remains a leading cause of preventable blindness in working-age adults, which is what makes screening so important. **Sources:** - [Diabetic Eye Disease](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-eye-disease) — NIH / NIDDK ### Diabetic kidney disease (nephropathy) **Diabetes is the leading cause of kidney failure; damage builds silently over years but can be slowed with early detection and protective treatment.** Diabetic kidney disease results from damage to the kidneys' tiny filtering vessels. It progresses silently: the first detectable sign is usually small amounts of the protein albumin in the urine, followed over years by a declining filtration rate (eGFR) and, in some, progression to kidney failure requiring dialysis or transplant. Diabetes is the single leading cause of kidney failure. Risk is amplified by high blood pressure, so the two are managed together. Early detection through yearly urine albumin and eGFR testing allows protective treatment — blood pressure and glucose control, plus medications (ACE inhibitors or ARBs, SGLT2 inhibitors, and newer agents) shown to slow decline and also reduce cardiovascular risk. As with other complications, the trajectory is far better when kidney disease is found and treated early rather than late. **Sources:** - [Diabetic Kidney Disease](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease) — NIH / NIDDK ### Diabetic neuropathy (nerve damage) **Nerve damage from diabetes can cause foot numbness and pain, digestive and bladder problems, and blunted warning signs of low blood sugar.** Neuropathy — nerve damage — is among the most common diabetes complications, affecting up to roughly half of people with diabetes over time. Peripheral neuropathy typically begins in the feet with numbness, tingling, burning, or pain and is a major contributor to foot ulcers and amputations because injuries go unfelt. Autonomic neuropathy disrupts the nerves that run internal organs, producing problems such as gastroparesis (delayed stomach emptying), constipation or diarrhea, bladder dysfunction, erectile dysfunction, abnormal sweating, dizziness on standing, and reduced awareness of hypoglycemia. Focal neuropathies can affect single nerves (for example causing carpal tunnel syndrome or sudden eye-muscle palsies). There is no cure for established nerve damage, so prevention through glucose, blood-pressure, and lipid control is central; symptoms such as neuropathic pain can be treated, and foot protection prevents downstream injury. **Sources:** - [What Is Diabetic Neuropathy?](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies/what-is-diabetic-neuropathy) — NIH / NIDDK ### Cardiovascular and large-vessel disease **Diabetes roughly doubles the risk of heart attack and stroke and is the leading cause of death in people with diabetes.** Macrovascular complications affect the large arteries, where diabetes accelerates atherosclerosis (the buildup of fatty plaque). This raises the risk of coronary heart disease and heart attack, stroke and transient ischemic attack, and peripheral artery disease (reduced blood flow to the legs, which contributes to foot complications and slow wound healing). Cardiovascular disease is the leading cause of death in people with diabetes, and the excess risk is driven by the combination of high glucose with high blood pressure, abnormal cholesterol, and smoking. Reducing it requires a whole-risk approach — glucose, blood pressure, and lipid control, not smoking, activity, and healthy eating — and, for many, statins and specific glucose-lowering drugs (GLP-1 receptor agonists and SGLT2 inhibitors) proven to cut cardiovascular events. Heart-protective care is as central to diabetes management as glucose itself. **Sources:** - [Preventing Diabetes Problems (heart disease and stroke)](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems) — NIH / NIDDK - [Diabetes Basics — heart disease and stroke risk](https://www.cdc.gov/diabetes/about/index.html) — CDC ### Other complications and associations **Diabetes is also linked to higher risks of infection, skin and gum problems, hearing loss, fatty liver disease, dementia, and sexual dysfunction.** Beyond the classic eye, kidney, nerve, and cardiovascular complications, diabetes is associated with a range of other problems. High glucose impairs immune defenses, raising the risk and severity of infections (skin, urinary, gum, and others) and slowing wound healing. Skin conditions and gum (periodontal) disease are more common. Diabetes is linked to non-alcoholic/metabolic fatty liver disease, certain cancers, obstructive sleep apnea, hearing loss, and an increased risk of cognitive decline and dementia. Sexual dysfunction — including erectile dysfunction and, in women, reduced sexual function — is common, often related to vascular and nerve damage. Depression and diabetes distress (covered under patient care) are also more frequent. Many of these risks are reduced by the same fundamentals: good glucose, blood-pressure, and lipid control, not smoking, vaccinations, and regular preventive care including dental and skin attention. **Sources:** - [Preventing Diabetes Problems (infections, skin, gums, and more)](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems) — NIH / NIDDK --- ## Comorbidities & Co-occurring Conditions What commonly co-occurs with diabetes and why it compounds: the cardiovascular–kidney–metabolic cluster, hypertension and abnormal lipids, obesity-linked conditions, depression and other mental health, autoimmune clustering in type 1, and the resulting polypharmacy. ### Diabetes rarely travels alone **Most people with diabetes have one or more other long-term conditions; these interact, so good care treats the whole person rather than glucose in isolation.** Diabetes commonly co-occurs with other chronic conditions, and modern guidelines build the assessment of comorbidities into routine diabetes care for that reason. The overlaps matter in two directions: diabetes raises the risk of conditions like heart disease, kidney disease, and depression, and those conditions in turn make diabetes harder to manage and worsen outcomes. They also create compounding and sometimes conflicting management considerations — a treatment that helps one condition may affect another, and several conditions together mean several medications and a heavier self-care load. This is why comprehensive diabetes care looks beyond glucose to blood pressure, lipids, kidney function, weight, mental health, and more, and why coordination across the care team is so important. The entries here map the most common co-occurring conditions and how they interact, as grounding for thinking about more than one condition at once. **Sources:** - [4. Comprehensive Medical Evaluation and Assessment of Comorbidities (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S59/157568/4-Comprehensive-Medical-Evaluation-and-Assessment) — American Diabetes Association — Diabetes Care, 2025 - [Preventing Diabetes Problems (multiple body systems)](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems) — NIH / NIDDK ### The diabetes–heart–kidney cluster _(Established)_ **Diabetes, heart disease, and chronic kidney disease form an extremely common, tightly linked cluster; they share drivers and worsen one another, but some treatments help all three at once.** Type 2 diabetes, cardiovascular disease, and chronic kidney disease frequently occur together — so often that they are increasingly described as a single cardiovascular–kidney–metabolic syndrome. They share underlying drivers (insulin resistance, high blood pressure, abnormal lipids, inflammation, and blood-vessel damage) and each accelerates the others: diabetes damages the heart and kidneys, kidney disease worsens blood pressure and cardiovascular risk, and heart failure and kidney disease complicate each other. This compounding is why management is coordinated rather than siloed, and it shapes drug choice in a helpful way: SGLT2 inhibitors and GLP-1 receptor agonists are favored precisely because they lower glucose while also reducing cardiovascular events, heart-failure hospitalization, and kidney-disease progression, and blood-pressure drugs like ACE inhibitors/ARBs protect both heart and kidney. The flip side is added complexity — overlapping risks, more medications, and the need to watch kidney function and volume status — so this cluster is the prime example of why multi-condition diabetes care must be integrated. **Sources:** - [10. Cardiovascular Disease and Risk Management (Standards of Care 2025)](https://diabetesjournals.org/care/article/48/Supplement_1/S207/157549/10-Cardiovascular-Disease-and-Risk-Management) — American Diabetes Association — Diabetes Care, 2025 - [Diabetic Kidney Disease (diabetes, kidney, and heart links)](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease) — NIH / NIDDK ### High blood pressure and abnormal cholesterol _(Established)_ **Most people with type 2 diabetes also have high blood pressure and/or abnormal lipids; together these multiply cardiovascular and kidney risk, so they are managed alongside glucose.** High blood pressure (hypertension) and abnormal cholesterol/triglycerides (dyslipidemia) are so common in type 2 diabetes that they are considered part of the standard picture rather than separate surprises. Each independently raises the risk of heart attack, stroke, and kidney disease, and combined with diabetes they compound that risk substantially — which is why diabetes care targets all of them together (often summarized as the 'ABCs': A1c, Blood pressure, Cholesterol, plus stopping smoking). Management typically includes blood-pressure medicines (commonly ACE inhibitors or ARBs, which also protect the kidneys) and lipid-lowering therapy (commonly statins) for most adults with diabetes in the relevant age and risk groups, alongside lifestyle measures. Treating these companions of diabetes generally does more to prevent heart attacks and strokes than focusing on glucose alone, which is why they are central, not optional, parts of care. **Sources:** - [10. Cardiovascular Disease and Risk Management (blood pressure and lipids)](https://diabetesjournals.org/care/article/48/Supplement_1/S207/157549/10-Cardiovascular-Disease-and-Risk-Management) — American Diabetes Association — Diabetes Care, 2025 - [Manage Blood Sugar and the ABCs](https://www.cdc.gov/diabetes/treatment/index.html) — CDC ### Obesity and its related conditions _(Established)_ **Excess weight drives type 2 diabetes and travels with conditions like fatty liver disease and sleep apnea; addressing weight can improve several of them at once.** Obesity is closely tied to type 2 diabetes through insulin resistance, and it tends to bring a constellation of related conditions: metabolic dysfunction-associated steatotic liver disease (MASLD, formerly non-alcoholic fatty liver disease), obstructive sleep apnea, high blood pressure, abnormal lipids, and osteoarthritis, among others. These overlap and reinforce one another — for example, sleep apnea worsens blood pressure and glucose control, and fatty liver tracks with cardiovascular risk. The encouraging implication is that weight-centered management can improve several conditions together: substantial weight loss (through structured lifestyle programs, GLP-1 and dual GIP/GLP-1 medications, or metabolic surgery) improves glucose, blood pressure, lipids, fatty liver, and sleep apnea, and can push type 2 diabetes toward remission. Because of this shared root, evaluating and addressing weight is a high-leverage part of diabetes care, coordinated with screening for the conditions that accompany it. **Sources:** - [4. Comprehensive Medical Evaluation and Assessment of Comorbidities (obesity-related conditions)](https://diabetesjournals.org/care/article/48/Supplement_1/S59/157568/4-Comprehensive-Medical-Evaluation-and-Assessment) — American Diabetes Association — Diabetes Care, 2025 - [8. Obesity and Weight Management (Standards of Care 2025)](https://diabetesjournals.org/care/issue/48/Supplement_1) — American Diabetes Association — Diabetes Care, 2025 ### Depression and mental health _(Established)_ **Depression, anxiety, and diabetes distress are markedly more common with diabetes and worsen self-care and outcomes; the relationship runs both ways, so mental health is part of diabetes care.** Mental health conditions co-occur with diabetes far more often than with the general population, and the link is bidirectional: living with a demanding chronic illness raises the risk of depression, anxiety, and diabetes distress, and depression in turn makes the daily work of diabetes — monitoring, medication, food, activity — harder to sustain, which worsens glucose control and complication risk. This is a clear example of compounding: untreated depression undermines management of the physical condition, and poor glucose control can deepen low mood. Eating disorders, including unsafe insulin restriction, are an additional serious risk. Because of these interactions, guidelines recommend periodic screening for depression, anxiety, and diabetes distress and integrating mental health support into diabetes care. Treating the mental health side — through counseling, peer support, diabetes education, and, where appropriate, medication — often improves both wellbeing and physical outcomes, which is why it belongs in the core of multi-condition care, not the margins. **Sources:** - [5. Facilitating Positive Health Behaviors and Well-being (psychosocial care)](https://diabetesjournals.org/care/article/48/Supplement_1/S86/157563/5-Facilitating-Positive-Health-Behaviors-and-Well) — American Diabetes Association — Diabetes Care, 2025 - [Preventing Diabetes Problems (depression and diabetes)](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems) — NIH / NIDDK ### Autoimmune clustering (type 1) and other co-occurring conditions _(Established)_ **Type 1 diabetes clusters with other autoimmune conditions (thyroid disease, celiac), and diabetes overall is linked to higher risks of dementia, gum disease, and more.** Beyond the cardiometabolic and mental-health overlaps, diabetes co-occurs with several other conditions. In type 1 (an autoimmune disease), other autoimmune conditions cluster — most commonly autoimmune thyroid disease and celiac disease, but also others — so periodic screening for thyroid problems (and celiac when indicated) is part of type 1 care. Across diabetes types, associations include periodontal (gum) disease, which has a two-way relationship with glucose control; obstructive sleep apnea; an increased risk of cognitive decline and dementia; certain cancers; hearing loss; fatty liver disease; and sexual dysfunction. Frailty and multiple conditions become especially important in older adults, where goals are individualized and avoiding hypoglycemia takes priority. The practical point is that diabetes care includes looking for the specific conditions that tend to accompany it — screening guided by the diabetes type and the individual — so they can be caught and managed alongside the diabetes rather than in isolation. **Sources:** - [4. Comprehensive Medical Evaluation and Assessment of Comorbidities (associated conditions and screening)](https://diabetesjournals.org/care/article/48/Supplement_1/S59/157568/4-Comprehensive-Medical-Evaluation-and-Assessment) — American Diabetes Association — Diabetes Care, 2025 - [Preventing Diabetes Problems (gum disease, dementia, and more)](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems) — NIH / NIDDK ### Polypharmacy and coordinating multiple conditions **Several conditions mean several medications, raising interaction, side-effect, and adherence burdens; coordinated review — including by a pharmacist — keeps the combined plan coherent and safe.** Because diabetes so often comes with heart disease, kidney disease, high blood pressure, abnormal lipids, depression, and other conditions, many people end up taking numerous medications — a situation called polypharmacy. Each drug may be individually appropriate, but together they raise the risk of interactions (see the Key Drug Interactions section), cumulative side effects, and a self-care burden that can hurt adherence. Several conditions can also pull in different directions, where the ideal treatment for one must be balanced against its effect on another, and goals may need individualizing — for example, relaxing glucose targets in frail older adults to avoid dangerous lows. Managing this well relies on coordination: a care team that sees the whole picture, periodic medication review and reconciliation (a role pharmacists are especially suited to), deprescribing what is no longer needed, and simplifying regimens where possible. The combined plan — not any single condition's 'ideal' in isolation — is what good multi-condition care optimizes, always with professional oversight. > **Note:** When several conditions and medicines stack up, ask for a medication review with the care team or pharmacist — coordinating the whole plan is safer than optimizing one condition alone. **Sources:** - [4. Comprehensive Medical Evaluation and Assessment of Comorbidities (medication review, older adults)](https://diabetesjournals.org/care/article/48/Supplement_1/S59/157568/4-Comprehensive-Medical-Evaluation-and-Assessment) — American Diabetes Association — Diabetes Care, 2025 - [9. Pharmacologic Approaches to Glycemic Treatment (simplifying regimens)](https://diabetesjournals.org/care/article/48/Supplement_1/S181/157569/9-Pharmacologic-Approaches-to-Glycemic-Treatment) — American Diabetes Association — Diabetes Care, 2025 --- ## Experimental & Emerging Therapies Frontier directions in diabetes — disease-modifying immunotherapy for type 1, islet and stem-cell transplantation, and advances toward fuller automation — reported with honest evidence levels and a caution about unproven clinics. ### Teplizumab (Tzield) — delaying type 1 diabetes _(Established)_ **Teplizumab is the first drug shown to delay the onset of clinical type 1 diabetes in high-risk people, approved in the U.S. in 2022.** Teplizumab (brand name Tzield) is an anti-CD3 monoclonal antibody that modulates the immune attack on beta cells. In a randomized trial in relatives at high risk of type 1 diabetes (with islet autoantibodies and abnormal glucose tolerance — 'stage 2' disease), a single 14-day course delayed the median onset of clinical (stage 3) type 1 diabetes by about two years versus placebo, and longer follow-up showed a durable effect. On that basis the FDA approved teplizumab in November 2022 to delay stage 3 type 1 diabetes in adults and children aged 8 and older with stage 2 disease — the first disease-modifying therapy for type 1. It does not prevent diabetes permanently, is given by intravenous infusion, requires monitoring for side effects (such as low white-cell counts and infusion reactions), and depends on identifying at-risk people through autoantibody screening. It marks a shift toward intervening before the disease becomes clinical. **Sources:** - [An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa1902226) — New England Journal of Medicine, 2019 - [FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-tzield) — U.S. Food and Drug Administration, 2022 ### Islet transplantation (donislecel / Lantidra) _(Established)_ **Transplanting insulin-producing islet cells from donor pancreases can free some people with type 1 from insulin, but requires lifelong immunosuppression and donor tissue is scarce.** Islet transplantation infuses insulin-producing islet cells, isolated from deceased-donor pancreases, into the recipient's liver, where they can engraft and secrete insulin. In 2023 the FDA approved the first such cellular therapy, donislecel (Lantidra), for adults with type 1 diabetes who have severe, recurrent hypoglycemia and impaired awareness despite intensive management — the situation where the risk of dangerous lows justifies the approach. Some recipients achieve insulin independence, sometimes for years. The major limitations are that it requires lifelong immunosuppressive drugs (with their own risks), donor tissue is in very short supply, and results vary, so it is reserved for selected patients rather than being a general cure. Islet transplantation nonetheless proves the principle — replacing beta cells can restore glucose control — that newer stem-cell approaches aim to scale up. **Sources:** - [FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes) — U.S. Food and Drug Administration, 2023 - [LANTIDRA (donislecel) product information](https://www.fda.gov/vaccines-blood-biologics/lantidra) — U.S. Food and Drug Administration ### Stem-cell-derived islet therapy (e.g. VX-880 / zimislecel) _(Investigational)_ **Islet cells grown from stem cells aim to overcome the donor shortage; early-trial results show some people achieving insulin independence, but this remains investigational.** A leading research frontier is making insulin-producing islet cells from stem cells, which could provide an essentially unlimited supply and overcome the donor-tissue bottleneck of conventional islet transplantation. The most advanced example, VX-880 (zimislecel), infuses fully differentiated, stem-cell-derived islet cells; early clinical-trial reports describe participants restoring insulin production and some achieving insulin independence, a striking proof of concept. Important caveats remain: current approaches still require immunosuppression to prevent rejection, trials are small and ongoing, long-term safety and durability are not yet established, and the therapy is not approved or available outside research. Parallel efforts aim to protect transplanted cells from the immune system (encapsulation, gene editing) so that immunosuppression might eventually be avoided. This is genuinely promising but firmly investigational. > **Note:** Stem-cell islet therapy is investigational and available only through regulated clinical trials — not from commercial 'stem cell' clinics. **Sources:** - [Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (NCT04786262)](https://clinicaltrials.gov/study/NCT04786262) — ClinicalTrials.gov (U.S. National Library of Medicine) ### Advances toward fuller automation _(Emerging)_ **Research is pushing automated insulin delivery toward less user input — fully closed loops, dual-hormone systems, and faster insulins — narrowing the gap to an artificial pancreas.** Today's automated insulin delivery (AID) systems are 'hybrid' closed loops that still need users to announce meals. Active research aims to reduce that burden: fully closed-loop systems that handle meals automatically; 'dual-hormone' systems that deliver both insulin and glucagon to better prevent lows; faster-acting insulins and improved algorithms (including adaptive and machine-learning control) that respond more quickly; and simpler, smaller devices. Studies of more automated and bionic systems show further gains in time in range and reduced management effort. These advances make daily life with insulin-treated diabetes safer and easier and are steadily approaching the long-sought 'artificial pancreas,' though they manage rather than cure diabetes. Much of this work is moving from trials into approved devices. **Sources:** - [Automated Insulin Delivery Systems and Insulin Pumps (advances)](https://www.breakthrought1d.org/daily-management/t1d-technology/aid-insulin-pumps/) — Breakthrough T1D (formerly JDRF) ### Caution: unproven 'stem cell' and 'cure' clinics _(No convincing evidence)_ **Clinics marketing stem-cell 'cures' for diabetes outside regulated trials are not supported by evidence, can be expensive, and may be unsafe — legitimate cell therapies come through approved trials or licensed products.** The genuine progress in cell and immune therapy has been accompanied by a troubling rise in clinics — often marketed online and abroad — selling 'stem cell' treatments that claim to cure type 1 or type 2 diabetes. These offerings are generally not supported by credible evidence, are not approved by regulators, can cost large sums, and carry real safety risks, including infections, tumors, and serious harm from unregulated procedures. Legitimate cell therapies are either licensed products (like donislecel for specific patients) or available only through regulated clinical trials registered on databases such as ClinicalTrials.gov, with oversight and informed consent. Anyone considering an experimental therapy should discuss it with their own diabetes specialist and verify it is part of a properly approved trial. Skepticism toward any 'miracle cure' that asks for payment outside a trial is well warranted. > **Note:** Be wary of clinics selling stem-cell 'cures' for diabetes outside approved clinical trials — discuss any experimental therapy with your diabetes specialist first. **Sources:** - [FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes (context on approved vs unapproved)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes) — U.S. Food and Drug Administration, 2023 --- ## Complementary & Integrative Approaches Evidence-graded look at supplements commonly marketed for diabetes (cinnamon, berberine, chromium, alpha-lipoic acid, magnesium, and others), with interaction and hypoglycemia safety flags. Educational only. ### How to think about supplements for diabetes _(No convincing evidence)_ **No dietary supplement is proven to treat diabetes; some have weak evidence at best, and none should replace prescribed treatment — always tell the care team what you take.** Many supplements are marketed for blood sugar, but the evidence behind them is generally weak, inconsistent, or absent, and none is a substitute for proven diabetes treatment. The U.S. National Center for Complementary and Integrative Health (NCCIH) emphasizes a few principles: do not replace medical treatment with an unproven product; be aware that 'natural' does not mean safe or free of side effects; supplements can interact with medications and affect blood glucose, blood pressure, or kidney/liver function; product quality and labeling vary; and there are special cautions in pregnancy and before surgery. The single most important step is to tell every member of the care team about any supplement, because some can add to the glucose-lowering effect of diabetes medicines and cause hypoglycemia, while others can interfere with treatment. Supplements may be considered only as a possible adjunct, never a replacement, and with medical input. > **Note:** Supplements are not a substitute for prescribed diabetes treatment. Tell your care team about anything you take — some can cause hypoglycemia or interact with medicines. **Sources:** - [Diabetes and Dietary Supplements: What You Need To Know](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements) — NIH / NCCIH ### Cinnamon _(No convincing evidence)_ **Despite popular claims, research on cinnamon for blood sugar is inconsistent and does not show a reliable benefit; large amounts of cassia cinnamon may also harm the liver.** Cinnamon is one of the most popular supplements promoted for blood sugar, but the evidence does not support a dependable effect: clinical studies have been small and mixed, and reviews conclude cinnamon has not been shown to reliably improve glucose control or A1c. There is also a safety consideration — cassia cinnamon (the common, cheaper type) contains coumarin, which in large or prolonged doses may be harmful to the liver, particularly for people with liver problems or on certain medications. Cinnamon as a spice in food is fine for flavor, but it should not be relied on as a treatment, and high-dose supplements are not recommended as a way to manage diabetes. As always, anyone taking it should mention it to their care team. > **Note:** High-dose cassia cinnamon supplements can stress the liver; cinnamon is not a proven diabetes treatment. **Sources:** - [Diabetes and Dietary Supplements (cinnamon)](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements) — NIH / NCCIH ### Berberine _(Preliminary)_ **Berberine is a plant compound with some studies suggesting a glucose-lowering effect, but evidence quality is limited and it has notable drug interactions and side effects.** Berberine, a compound found in plants such as goldenseal and barberry, has attracted attention because some small trials suggest it can lower blood glucose, possibly through effects on the same pathways as metformin. However, the evidence base is limited by small, lower-quality studies, and berberine is not an established or approved treatment. Importantly, it is not benign: it commonly causes gastrointestinal side effects, and it interacts with many medications by inhibiting drug-metabolizing enzymes (it can raise levels of various drugs), and may add to the glucose-lowering effect of diabetes medicines, increasing hypoglycemia risk. It should be avoided in pregnancy and breastfeeding. Because of these interactions and safety questions, berberine should only be considered, if at all, in consultation with the care team — not self-started as a replacement for prescribed treatment. > **Note:** Berberine has significant drug interactions and can add to glucose-lowering medicines (hypoglycemia risk); avoid in pregnancy. Discuss with the care team before use. **Sources:** - [Diabetes and Dietary Supplements (herbal supplements / berberine)](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements) — NIH / NCCIH ### Chromium _(Mixed evidence)_ **Chromium supplements have been studied for blood sugar with inconsistent results; there is no strong evidence of benefit for people who are not chromium-deficient.** Chromium is a trace mineral involved in carbohydrate metabolism, and chromium picolinate is widely sold for blood sugar. Research results are inconsistent: some studies suggest small effects on glucose and others show none, and overall the evidence does not establish a meaningful benefit for managing diabetes, especially in people who are not deficient (deficiency is rare with a normal diet). High doses have been associated with side effects and, rarely, kidney problems. NCCIH's assessment is that the evidence is weak and chromium should not be relied upon to treat diabetes. As with other supplements, it should be discussed with the care team and never substituted for proven treatment. **Sources:** - [Diabetes and Dietary Supplements (chromium)](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements) — NIH / NCCIH ### Alpha-lipoic acid _(Mixed evidence)_ **Alpha-lipoic acid is studied mainly for diabetic neuropathy symptoms rather than blood sugar; evidence is limited and it can interact with diabetes medicines.** Alpha-lipoic acid (ALA) is an antioxidant that has been studied most for symptoms of diabetic peripheral neuropathy (such as pain, burning, and numbness), where some trials — particularly with intravenous forms — suggest possible symptom relief, though oral evidence is weaker and overall results are not conclusive. It is not an established treatment for diabetes itself or a reliable way to lower blood glucose. Safety points: ALA may lower blood glucose, so combined with diabetes medication it could contribute to hypoglycemia, and it may interact with thyroid medication and others. Because the evidence is limited and there are interaction considerations, ALA should only be used with medical input, as a possible adjunct for neuropathy symptoms rather than a glucose treatment, and never as a replacement for prescribed care. > **Note:** Alpha-lipoic acid may lower blood glucose and interact with thyroid and other medicines — use only with care-team input. **Sources:** - [Diabetes and Dietary Supplements (alpha-lipoic acid)](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements) — NIH / NCCIH ### Magnesium, omega-3s, vitamin D, and others _(No convincing evidence)_ **Correcting a true magnesium deficiency matters, but routine supplements — magnesium, omega-3s, vitamin D — have not been shown to prevent or treat diabetes in well-nourished people.** Several other supplements are commonly discussed. Low magnesium is associated with poorer glucose control, and correcting a documented deficiency is reasonable, but routine magnesium supplementation has not been shown to treat diabetes in people who are not deficient. Omega-3 fatty acids (fish oil) benefit some cardiovascular risk markers but have not been shown to improve blood glucose control or prevent diabetes. Vitamin D supplementation, despite interest, has not been shown to prevent type 2 diabetes in people who are not deficient. Other remedies (bitter melon, fenugreek, ginseng, and many 'blood sugar support' blends) have only weak or preliminary evidence and variable, sometimes unsafe, product quality — some blends have even been found adulterated with hidden pharmaceuticals. The consistent message is to prioritize proven treatment and a healthy diet, address genuine deficiencies, and review any supplement with the care team for interactions and hypoglycemia risk. > **Note:** Some 'blood sugar support' products have been found adulterated with hidden drugs. Prioritize proven treatment and review supplements with the care team. **Sources:** - [Diabetes and Dietary Supplements (magnesium, omega-3s, vitamin D, others)](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements) — NIH / NCCIH --- _Educational synthesis from reputable public sources._ _Nurse Joy condition guide — educational reference. Not medical advice._